STAT January 11, 2024
Elaine Chen

A preliminary evaluation by the Food and Drug Administration did not find evidence that GLP-1 drugs like Ozempic and Wegovy cause suicidal thoughts or actions.

The regulator has been reviewing reports of patients experiencing suicidal ideations while using this class of diabetes and obesity treatments, but because there was limited information provided and because other factors could be influencing the suicidal thoughts, the FDA determined that there was no clear link to the drugs, it said in a post Thursday. A review of trials and studies conducted on the medications also didn’t find a link to suicidal thoughts and actions.

The FDA said it can’t definitively rule out that a small risk may exist, though, and so it’s continuing to...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Patient / Consumer, Pharma, Pharma / Biotech, Provider
MHE Week in Review – New PBM Reform Bill, Cardiac Diseases Cost
Deep learning uncovers gene targets and potential drugs to slow brain aging
FDA issues flu vaccine recommendations: 5 respiratory updates
CZI’s Priscilla Chan on ‘Virtual Cells’ AI Models to Cure Diseases
HIMSSCast: The 'genetic revolution' is underway

Share This Article